ShadowDiviner72
3 months ago
I think data was as expected. Look, cancer patients on TARGETED therapies have a 95% chance of getting CID. Breast and Lung cancer patients in ONTARGET received TARGETED therapies. So, if it worked on 75% of the patients. Which is the group were 95% of the patients get CID, the trial is succesfull... simple.
HOWEVER, I exited my position for the following reason: In my opinion there was not shared any detailed information, because the principal investigator wants to take the data to SABCS (breast cancer symposium), like they did with the phase 2 trial.
I've seen it with other stocks that the principal investigators prefere this. And they decide where data is presented. So in my opinion we can wait for the full data till december 9th (SABCS)
So, unless the POC data for SBS and MVIS shows up, or a a new partnership... it will be a long wait, and shorts will take it down again. That's why I chose to exit, but I will be back in november
missy68
3 months ago
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (βJaguarβ) today announced the results from its initial analysis of the pivotal Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy. Crofelemer is an FDA-approved prescription drug for the symptomatic relief of diarrhea in adult HIV/AIDS patients receiving antiretroviral therapy. The initial results from the OnTarget study show that the multicenter, double-blind, placebo-controlled pivotal clinical trial did not meet its primary endpoint for the prespecified analysis of all tumor types in the trial.
βWhile the results of the OnTarget study did not achieve significance for all tumor types receiving various targeted therapies, I am pleased that the subgroup analyses show that crofelemer provides clinically meaningful improvement in the prespecified subgroups of breast and respiratory tumor patients. Clinical meaningfulness of these results is based on the information provided by solid tumor patients from a survey that informed us about the appropriate clinical study design and clinical endpoints, that are important to the patients in this prophylactic trial. We will continue to evaluate important OnTarget findings, with further analyses,β said Pablo Okhuysen, MD, Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, who is the Principal Investigator of the OnTarget clinical trial. βIt is important to note that the prespecified secondary outcomes for this study were based on outcomes that were considered to be meaningful by patients experiencing diarrhea due to targeted therapy.β
KEY TAKE-A-WAYS FROM ONTARGET TRIAL
Β· Unprecedented OnTarget trial included patients with 10 different tumor types and 24 different targeted agents, with and without multiple standard cytotoxic chemotherapies.
Β· Study did not meet prespecified analysis of primary endpoint for all tumor types.
Β· Analysis did reveal clinically relevant signals for patients in the prespecified subgroups of breast and respiratory cancers, including lung cancer, who received targeted therapies. These subgroups of patients comprised over 75% of the patients in the trial.
Β· Breast and lung cancers are two of the three most common cancers, with patients often remaining on targeted therapy over prolonged periods.
Β· A growing and urgent unmet medical need exists for novel non-opioid chronic agents to treat CTD.
Β· Results indicate positive signals improved over the initial 12-week phase of study; data for additional 12-week extension phase yet to be analyzed.
Β· Company expects to engage with FDA after full review of data.
timberwolf7
3 months ago
Not a lot of folks 'paying' attention this morning based on the volume activity..
Going to be interesting to see what the company says if anything about the potential
revenue from this product if the PH 3 is good..
I see someone said BILLIONS.... I would be hesitant with this number and wait for
the company to give their projection
Note: given their CURRENT low revenue numbers, and the low activity/interest level,
I would expect this to get shorted post the announcement. Especially since I would
expect them to do a secondary offering to raise cash (dilution)
Disclaimer: I decided yesterday based on the 'low interest'/trading, to lock in the gains I had.
Yes, I might miss something, but if this pops on the open?? I wouldn't be slow to take at least
some of the gains you get. And if I am wrong, won't be the first time I mis-read something.
GOOD LUCK